**MULTIPLE ENDOCRINE NEOPLASIA TYPE 4**

**Wouter W. de Herder, MD, PhD**, Professor of Endocrine Oncology, Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands. [w.w.deherder@erasmusmc.nl](mailto:w.w.deherder@erasmusmc.nl)

**Johannes Hofland, MD, PhD,** Endocrinologist, Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, and Erasmus MC Cancer Institute Rotterdam, the Netherlands. [j.hofland@erasmusmc.nl](mailto:j.hofland@erasmusmc.nl)

**Updated April 14, 2025**

**ABSTRACT**

MEN4 (OMIM #610755) has many similarities with MEN1 but is caused by germline mutations in *CDKN1B*. MEN4 is rarer than MEN1. Clinical manifestations of MEN4 encompass primary hyperparathyroidism, pituitary adenomas, and gastroenteropancreatic neuroendocrine neoplasms. In line with MEN1 other neoplasms may occur.

**INTRODUCTION**

MEN4 (OMIM #610755) was initially named MENX and was first described in rats (1-3). MEN4 is caused by germline mutations in *CDKN1B* (*Cdkn1b* in rats), a tumor suppression gene encoding for the protein p27Kip1 (commonly referred to as p27 or as KIP1) (4). The *CDKN1B* gene is located on chromosome 12p13.1 (5). p27 is a member of the cyclin-dependent kinase inhibitor (CDKI) family which regulates the cell cycle (6, 7). Germline mutations in *CDKN1B* lead to reduced expression of p27, thereby resulting in uncontrolled cell cycle progression. To date, most of the reported human mutations were missense. These mutations were deemed pathogenic due to their *in vivo* or *in vitro* effects on the function of p27. In humans, two CDKI families have been identified: the INK4a/ARF family and the Cip/Kip family (8). Natalia Pellegata and colleagues reported in 2006 a three-generation family with apparently MEN1-related tumors, but this kindred turned out to become the first reported cases of MEN4 in humans (2). The incidence of *CDKN1B* mutations in patients with a MEN1-related phenotype is likely to be in the range of 1-4% (9-11). MEN4 screening has been recommended for all patients with a MEN1-related phenotype without the presence of a MEN1 gene mutation, but the yield seems to be extremely low (< 0.1%) (12, 13). All first-degree relatives of patients with MEN4 should be offered genetic testing (14-16). The offspring of an individual with MEN4 has a 50% chance of inheriting the *CDKN1B* pathogenic variant (17). Possible genotype-phenotype correlations might exist (18).

**CLINICAL FEATURES OF MEN4**

**Primary Hyperparathyroidism**

Primary hyperparathyroidism has been reported in up to 80%-90% of cases with MEN4 (3). The indications for parathyroid surgery in MEN4 are the same as for MEN1 and the approach in MEN4-related primary hyperparathyroidism may be similar to that in MEN1 (19-22). It is suggested that screening for hyperparathyroidism with serum calcium measurements (and parathyroid hormone levels (PTH) if indicated) should start at the age of 15 years in MEN4 mutation carriers (23, 24).

**Pituitary Adenomas**

Pituitary involvement in MEN4 is the second most common manifestation of the disease, affecting approximately 1/3 of the reported cases to date. The types of pituitary disorders in MEN4 include: nonfunctional pituitary adenoma, acromegaly and gigantism, prolactinoma, or Cushing’s disease (16, 22, 25-36). Pituitary tumors in MEN4 generally present with less aggressiveness and smaller size compared to those in MEN1 (28). The management of pituitary tumors in MEN4 is similar to other sporadic or familial cases (19). Routine surveillance for the development of pituitary tumors in patients with MEN4 should be performed on a case-by-case basis and follow the current guidelines for MEN1 (19, 24).

**Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs)**

The prevalence of GEP NENs in MEN4 is approximately 25%. These include gastroduodenal or pancreatic NENs (panNENs), which are either nonfunctioning or secreting several peptides and hormones, including gastrin, insulin, adrenocorticotropic hormone (ACTH), or vasoactive intestinal polypeptide (VIP) (11, 20, 22, 25, 37-39). It appears that there is a decreased penetrance of gastroduodenal NENs or panNENs in MEN4 as compared to MEN1. The clinical syndromes associated with these hormonal overproductions can be found elsewhere in *Endotext* (40-43). The diagnosis and management of panNENs in MEN4 is similar to that in MEN1 (19). Screening for gastroduodenal NENs and panNENs should be initiated according to MEN1 screening protocols (19).

**Other Neoplasms**

Cervical neuroendocrine carcinoma (NEC), secreting and nonsecreting adrenal tumors, testicular cancer, breast cancer, papillary and medullary thyroid cancer, colon cancer, thymic and lung carcinoids, and meningioma have been reported incidentally in MEN4 cases (2, 9, 11, 15, 22, 23, 34, 36, 44, 45).

**REFERENCES**

1. Fritz A, Walch A, Piotrowska K, Rosemann M, Schäffer E, Weber K, et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002;62(11):3048-51.

2. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(42):15558-63.

3. Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013;41:63-78.

4. Bencivenga D, Stampone E, Azhar J, Parente D, Ali W, Del Vecchio V, et al. p27(Kip1) and Tumors: Characterization of CDKN1B Variants Identified in MEN4 and Breast Cancer. Cells. 2025;14(3).

5. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res. 2001;264(1):148-68.

6. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996;271(5257):1861-4.

7. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78(1):59-66.

8. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-12.

9. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321-5.

10. Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat. 2010;31(11):E1825-35.

11. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94(5):1826-34.

12. Chevalier B, Coppin L, Romanet P, Cuny T, Maïza JC, Abeillon J, et al. Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review. J Clin Endocrinol Metab. 2024;109(7):e1482-e93.

13. Faggiano A, Fazzalari B, Mikovic N, Russo F, Zamponi V, Mazzilli R, et al. Clinical Factors Predicting Multiple Endocrine Neoplasia Type 1 and Type 4 in Patients with Neuroendocrine Tumors. Genes (Basel). 2023;14(9).

14. de Laat JM, van der Luijt RB, Pieterman CR, Oostveen MP, Hermus AR, Dekkers OM, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14(1):182.

15. Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer. 2017;24(10):T195-t208.

16. Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics. Neuroendocrinology. 2016;103(1):18-31.

17. Brock P, Kirschner L. Multiple Endocrine Neoplasia Type 4. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle; 1993.

18. Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A, et al. Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer. 2023;30(1).

19. Pieterman CRC, van Leeuwaarde RS, van den Broek MFM, van Nesselrooij BPM, Valk GD. Multiple Endocrine Neoplasia Type 1. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

20. Tonelli F, Giudici F, Giusti F, Marini F, Cianferotti L, Nesi G, et al. A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. Eur J Endocrinol. 2014;171(2):K7-k17.

21. Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto MR, Barcons S, Guirao X, et al. Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism. J Endocrinol Invest. 2023;46(4):829-40.

22. Seabrook A, Wijewardene A, De Sousa S, Wong T, Sheriff N, Gill AJ, et al. MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. J Clin Endocrinol Metab. 2022;107(8):2339-49.

23. Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker RV, Frost M. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J Clin Endocrinol Metab. 2019;104(9):3637-46.

24. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2):2-15.

25. Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S, et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 2013;9(3):e1003350.

26. Crona J, Gustavsson T, Norlén O, Edfeldt K, Åkerström T, Westin G, et al. Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2015;22 Suppl 3:S1428-35.

27. Sambugaro S, Di Ruvo M, Ambrosio MR, Pellegata NS, Bellio M, Guerra A, et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region. Endocrine. 2015;49(1):58-64.

28. Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78(5):457-63.

29. Ikeda H, Yoshimoto T, Shida N. Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer. 1997;76(9):1119-23.

30. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG, et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene. 1998;16(1):69-76.

31. Lindberg D, Akerström G, Westin G. Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function. Neoplasia. 2007;9(7):533-5.

32. Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S, Shimon I. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol. 1998;157(2):337-41.

33. Chasseloup F, Pankratz N, Lane J, Faucz FR, Keil MF, Chittiboina P, et al. Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype. J Clin Endocrinol Metab. 2020;105(6):1983-2005.

34. Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea ML, et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer. 2012;19(3):233-41.

35. De Sousa SMC. From bench to bedside in the sella: translational developments in pituitary tumour genetics. Endocr Relat Cancer. 2025.

36. Mercè F, Asla Q, Illana FJ, Victòria F, Javier HL, Marta S, et al. A novel likely pathogenic germline variant in CDKN1B in a patient with MEN4 and medullary thyroid cancer. Fam Cancer. 2025;24(1):24.

37. Malanga D, De Gisi S, Riccardi M, Scrima M, De Marco C, Robledo M, et al. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol. 2012;166(3):551-60.

38. Belar O, De La Hoz C, Pérez-Nanclares G, Castaño L, Gaztambide S. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol (Oxf). 2012;76(5):719-24.

39. Han HJ, Moalem J, Shih AR, Gigliotti BJ. Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4. AACE Clin Case Rep. 2025;11(2):93-7.

40. Jensen RT, Ito T. Gastrinoma. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

41. de Herder WW, Hofland J. Insulinoma. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

42. de Herder WW, Hofland J. Vasoactive Intestinal Peptide-Secreting Tumor (VIPoma). In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

43. Tsoli M, Dimitriadis GK, Androulakis, II, Kaltsas G, Grossman A. Paraneoplastic Syndromes Related to Neuroendocrine Tumors. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

44. Desrosiers-Battu LR, Lee JH, Tarasiewicz I, Gilbert AR, Galvan EM, Singh AK, et al. Anaplastic meningioma in a 6-year-old with somatic YAP1::MAML2 fusion and multiple endocrine neoplasia type 4 (MEN4) syndrome. Cancer Genet. 2025;292-293:106-10.

45. Singeisen H, Renzulli MM, Pavlicek V, Probst P, Hauswirth F, Muller MK, et al. Multiple endocrine neoplasia type 4: a new member of the MEN family. Endocr Connect. 2023;12(2).